Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
Langmuir : the ACS Journal of Surfaces and Colloids|January 17, 2020
An Atomistic Molecular Dynamics Study of Titanium Dioxide Adhesion to Lipid BilayersMichelle P Aranha, Dibyendu Mukherjee, Loukas Petridis, et al.Vaccine|August 18, 2023
Structure-guided design of a broadly cross-reactive multivalent group a streptococcal vaccineJames B Dale, Michelle P Aranha, Thomas A Penfound, et al.Biochimica Et Biophysica Acta. General Subjects|January 20, 2020
Prediction of peptide binding to MHC using machine learning with sequence and structure-based feature setsMichelle P Aranha, Catherine Spooner, Omar Demerdash, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 3, 2021
Design of Broadly Cross-Reactive M Protein-Based Group A Streptococcal VaccinesMichelle P Aranha, Thomas A Penfound, Sanaz Salehi, et al.The Journal of Biological Chemistry|February 8, 2020
Structure-based group A streptococcal vaccine design: Helical wheel homology predicts antibody cross-reactivity among streptococcal M protein-derived peptidesMichelle P Aranha, Thomas A Penfound, Jay A Spencer, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 4, 2020
Combining Three-Dimensional Modeling with Artificial Intelligence to Increase Specificity and Precision in Peptide-MHC Binding PredictionsMichelle P Aranha, Yead S M Jewel, Robert A Beckman, et al.Vaccine|March 1, 2021
Cross-reactive immunogenicity of group A streptococcal vaccines designed using a recurrent neural network to identify conserved M protein linear epitopesJay A Spencer, Tom Penfound, Sanaz Salehi, et al.Biorxiv : the Preprint Server for Biology|August 14, 2023
Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitorsRomanos Sklavenitis-Pistofidis, Elizabeth D Lightbody, Mairead Reidy, et al.Medrxiv : the Preprint Server for Health Sciences|May 3, 2024
Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and DexamethasoneOmar Nadeem, Michelle P Aranha, Robert Redd, et al.Nature Chemical Biology|May 28, 2026
Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myelomaMichael P Agius, Chen Song, Qi Liu, et al.Pageof 2